{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:28:39Z","timestamp":1786991319957,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019294","name":"Office of Rural Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["CIN 13-412"],"award-info":[{"award-number":["CIN 13-412"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jaip.2021.08.006","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T14:12:33Z","timestamp":1629382353000},"page":"222-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA"],"prefix":"10.1016","volume":"10","author":[{"given":"Nicola A.","family":"Hanania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Fortis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tmirah","family":"Haselkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayla","family":"Mumneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile T.J.","family":"Holweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley E.","family":"Chipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.08.006_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4103\/lungindia.lungindia_184_18","article-title":"Determining the optimal time to assess the reversibility of airway obstruction","volume":"36","author":"El Ghoul","year":"2019","journal-title":"Lung India"},{"key":"10.1016\/j.jaip.2021.08.006_bib3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3109\/02770903.2014.895012","article-title":"Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses","volume":"51","author":"Tashkin","year":"2014","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2021.08.006_bib4","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1378\/chest.07-0713","article-title":"Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study","volume":"132","author":"Lee","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2021.08.006_bib5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4103\/atm.ATM_22_18","article-title":"Assessment of proximal and peripheral airway dysfunction by computed tomography and respiratory impedance in asthma and COPD patients with fixed airflow obstruction","volume":"13","author":"Pornsuriyasak","year":"2018","journal-title":"Ann Thorac Med"},{"key":"10.1016\/j.jaip.2021.08.006_bib6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12931-018-0880-2","article-title":"Steroid insensitive fixed airflow obstruction is not related to airway inflammation in older non-smokers with asthma","volume":"19","author":"Tonga","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2021.08.006_bib7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1183\/09031936.00146905","article-title":"Clinical relevance of airway remodelling in airway diseases","volume":"30","author":"James","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2021.08.006_bib8","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1183\/13993003.01709-2015","article-title":"Airflow obstruction is associated with increased smooth muscle extracellular matrix","volume":"47","author":"Jones","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2021.08.006_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaci.2009.03.049","article-title":"Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction","volume":"124","author":"Kaminska","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.08.006_bib10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After asthma: redefining airways diseases","volume":"391","author":"Pavord","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.08.006_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.anai.2017.10.004","article-title":"Risk factors and clinical outcomes associated with fixed airflow obstruction in older adults with asthma","volume":"120","author":"Bennett","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.08.006_bib12","first-page":"9868704","article-title":"Risk Factors associated with irreversible airway obstruction in asthma: a systematic review and meta-analysis","volume":"2016","author":"Zhang","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jaip.2021.08.006_bib13","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.rmed.2015.09.009","article-title":"Persistent airflow obstruction in patients with asthma: characteristics of a distinct clinical phenotype","volume":"109","author":"Konstantellou","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2021.08.006_bib14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jaci.2010.01.003","article-title":"Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up","volume":"125","author":"Contoli","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.08.006_bib15","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00108514","article-title":"Asthma, airflow limitation and mortality risk in the general population","volume":"45","author":"Huang","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2021.08.006_bib16","first-page":"PA576","article-title":"Risk factors of fixed airway obstruction in elderly patients with asthma","volume":"48","author":"Song","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2021.08.006_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness","volume":"12","author":"Pelaia","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaip.2021.08.006_bib18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2021.08.006_bib19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.08.006_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.08.006_bib21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2021.08.006_bib22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.08.006_bib23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.anai.2019.11.016","article-title":"Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma","volume":"124","author":"Busse","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.08.006_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12890-019-0906-7","article-title":"Severe exacerbations in moderate-to-severe asthmatics are associated with increased pro-inflammatory and type 1 mediators in sputum and serum","volume":"19","author":"Ghebre","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2021.08.006_bib25","doi-asserted-by":"crossref","first-page":"1902119","DOI":"10.1183\/13993003.02119-2019","article-title":"Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD","volume":"55","author":"Mathioudakis","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2021.08.006_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13223-018-0315-0","article-title":"Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control","volume":"14","author":"Wei","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2021.08.006_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1399-3003.1999.14a06.x","article-title":"What are minimal important changes for asthma measures in a clinical trial?","volume":"14","author":"Santanello","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2021.08.006_bib28","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2021.08.006_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.anai.2019.10.006","article-title":"Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma","volume":"124","author":"Chipps","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.08.006_bib30","doi-asserted-by":"crossref","first-page":"1702523","DOI":"10.1183\/13993003.02523-2017","article-title":"Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study","volume":"51","author":"Humbert","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2021.08.006_bib31","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1513\/AnnalsATS.201809-601OC","article-title":"Combined forced expiratory volume in 1 second and forced vital capacity bronchodilator response, exacerbations, and mortality in chronic obstructive pulmonary disease","volume":"16","author":"Fortis","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2021.08.006_bib32","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1164\/rccm.201804-0663OC","article-title":"Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study","volume":"198","author":"Wan","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2021.08.006_bib33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12931-016-0468-7","article-title":"Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study","volume":"17","author":"Sood","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2021.08.006_bib34","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2011.12.986","article-title":"Asthma outcomes: pulmonary physiology","volume":"129","author":"Tepper","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821009053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821009053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:31:23Z","timestamp":1761975083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821009053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2213219821009053"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.08.006","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}